Clinical Trials Logo

Clinical Trial Summary

This is a continuous dosing Phase I Study of BMS-599626 in patients with HER2-expressing advanced solid malignancies.


Clinical Trial Description

n/a


Study Design

Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment


Related Conditions & MeSH terms

  • HER2 or EGFR Expressing Advanced Solid Malignancies
  • Neoplasms

NCT number NCT00207012
Study type Interventional
Source Bristol-Myers Squibb
Contact
Status Completed
Phase Phase 1
Start date May 2004